Publications by authors named "R Kreienberg"
Article Synopsis
- This study evaluated the five-year overall, recurrence, and distant metastasis-free survival rates of high- and intermediate-risk breast cancer patients who chose not to undergo recommended adjuvant chemotherapy.
- Conducted as part of the BRENDA II multicenter cohort study from 2009 to 2012, findings were based on a total of 759 patients, analyzing the impact of chemotherapy decisions made by a multi-professional tumorboard team.
- Results showed that while there were no significant differences in overall survival and metastasis-free survival for patients who declined chemotherapy, those who followed the guidelines and received chemotherapy experienced a significantly better five-year recurrence-free survival.
BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients.
Cancers (Basel)
June 2021
Background Current research in breast cancer focuses on individualization of local and systemic therapies with adequate escalation or de-escalation strategies. As a result, about two-thirds of breast cancer patients can be cured, but up to one-third eventually develop metastatic disease, which is considered incurable with currently available treatment options. This underscores the importance to develop a metastatic recurrence score to escalate or de-escalate treatment strategies.
View Article and Find Full Text PDFTo which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
Breast Cancer Res Treat
February 2021
Objective: In this study, we investigated to which extent patients feel well informed about their disease and treatment, which areas they wish more or less information and which variables are associated with a need for information about the disease, medical tests and treatment.
Methods: In a German multi-centre prospective study, we enrolled 759 female breast cancer patients at the time of cancer diagnosis (baseline). Data on information were captured at 5 years after diagnosis with the European Organisation for Research and Treatment of Cancer (EORTC) Information Module (EORTC QLQ-INFO24).
Background: Breast cancer patients' self-understanding of their disease can impact their quality of life (QoL); the relationship between compliance and QoL is poorly understood.
Patients And Methods: The Patient's Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated the effect of additional patient information material (IM) packages on compliance with adjuvant aromatase inhibitor (AI) therapy in postmenopausal women with hormone receptor-positive early breast cancer. The QoL subanalysis presented here examined the impact of IM packages on QoL and the association between QoL and compliance.